Immunotherapy for prostate cancer.
The components of an effective immune response have been elucidated in recent years. An understanding of the dysfunction of the immune response in cancer in one or more of these components has led to a variety of immunotherapeutic approaches. These therapeutic strategies are designed to stimulate dendritic cell proliferation, promote antigen uptake and processing, stimulate an effector cell response via direct antigen presentation, or target tumor cells via antibody therapy. Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen.
Rini
B I
BI
University of California at San Francisco Comprehensive Cancer Center, 1600 Divisidero Street, 3rd floor, San Francisco, CA 94115, USA. brini@medicine.ucsf.edu
Small
E J
EJ
D017951:Antigen Presentation / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor